Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

<p>Multivariable Cox proportional hazards models for time to progression and time to death</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Sofie H. Tolmeijer (15313251) (author)
Άλλοι συγγραφείς:	Emmy Boerrigter (15313254) (author), Takayuki Sumiyoshi (15034119) (author), Edmond M. Kwan (15313257) (author), Sarah W.S. Ng (14960841) (author), Matti Annala (15313260) (author), Gráinne Donnellan (15313263) (author), Cameron Herberts (14960820) (author), Guillemette E. Benoist (15313266) (author), Paul Hamberg (15313269) (author), Diederik M. Somford (15035198) (author), Inge M. van Oort (15035171) (author), Jack A. Schalken (15313272) (author), Niven Mehra (15011036) (author), Nielka P. van Erp (15313275) (author), Alexander W. Wyatt (14960922) (author)
Έκδοση:	2025
Θέματα:	Cancer Cancer Detection and Diagnosis Methods and Technology Biomarkers Circulating tumor cells/DNA/exosomes Genitourinary Cancers Prostate cancer Liquid Biopsy
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
ανά: Sofie H. Tolmeijer (15313251)
Έκδοση: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
ανά: Sofie H. Tolmeijer (15313251)
Έκδοση: (2025)

Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
ανά: Ismael Fernández-Miranda (15051932)
Έκδοση: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
ανά: Andrew A. Davis (15030032)
Έκδοση: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
ανά: Nam Q. Bui (14958210)
Έκδοση: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
ανά: Lavanya Sivapalan (15314248)
Έκδοση: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
ανά: Morten Lapin (15056728)
Έκδοση: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
ανά: Morten Lapin (15056728)
Έκδοση: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
ανά: Morten Lapin (15056728)
Έκδοση: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
ανά: Jun Wang (15051911)
Έκδοση: (2025)

Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
ανά: Cloud P. Paweletz (14960112)
Έκδοση: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Supplementary Table S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Supplementary Table S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
ανά: Katleen Janssens (15053356)
Έκδοση: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
ανά: Stephanie Lheureux (16797697)
Έκδοση: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
ανά: Stephanie Lheureux (16797697)
Έκδοση: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
ανά: Stephanie Lheureux (16797697)
Έκδοση: (2025)

Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
ανά: Stephanie Lheureux (16797697)
Έκδοση: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
ανά: Stephanie Lheureux (16797697)
Έκδοση: (2025)

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
ανά: Whitney L. Hensing (16461978)
Έκδοση: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
ανά: Ruiyun Zhang (17142498)
Έκδοση: (2025)

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
ανά: N. Ari Wijetunga (15056183)
Έκδοση: (2025)

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
ανά: N. Ari Wijetunga (15056183)
Έκδοση: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
ανά: N. Ari Wijetunga (15056183)
Έκδοση: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
ανά: N. Ari Wijetunga (15056183)
Έκδοση: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
ανά: Kala Visvanathan (14952973)
Έκδοση: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
ανά: Kala Visvanathan (14952973)
Έκδοση: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
ανά: Kala Visvanathan (14952973)
Έκδοση: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
ανά: Kala Visvanathan (14952973)
Έκδοση: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
ανά: Kala Visvanathan (14952973)
Έκδοση: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
ανά: Iris van 't Erve (15054503)
Έκδοση: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
ανά: Francesca Orzan (15055579)
Έκδοση: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
ανά: Francesca Orzan (15055579)
Έκδοση: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
ανά: Francesca Orzan (15055579)
Έκδοση: (2025)

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
ανά: Martin Sjöström (14845882)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_4d1n06gajto0uvbgmfeveu75n8